OpenAI Explores Massive Funding Round at $750 Billion Valuation 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Brooklyn, NY, Sept. 07, 2016 -- The ability of umbilical cord stem cells to overcome many of the shortcomings and complications associated with blood transfusion has helped in the creation of a global, multibillion dollar umbilical cord stem cells market. A new report that is now available on QYResearchReports.com studies in detail the factors that will encourage the growth of the global umbilical cord stem cells market and provides specific recommendations for growth. The report is titled, ‘Global Umbilical Cord Stem Cells Market Research Report 2021.’
Get Sample Copy of Report for more Professional and Technical insights : http://www.qyresearchreports.com/sample/sample.php?rep_id=787396&type=E
Although cord blood came into the spotlight in the late 1980s for proving useful in treating blood diseases in children, its real commercial potential was only realized several years later when it was observed that several disorders among adults could also be treated using cord blood. With the outcomes of adult umbilical cord blood transplantation having dramatically improved over the last decade, there is now a growing popular acceptance for it. This has resulted in an unprecedented number of public and private cord blood banks coming up, further driving the growth of the global umbilical cord stem cells market.
Despite a positive long-term outlook for the global umbilical cord stem cells market, there are a few challenges that may slow down the growth of the market. The greatest limitation currently is that blood from a single umbilical cord for the purpose of cord blood transplantation contains fewer haematopoeitic stem cells than what would be obtained via bone marrow donation. A common technique to counter this drawback is to obtain blood from two umbilical cords – a concept known as double cord blood transplant. Although this technique has shown encouraging results in clinical trials, it continues to limit the scope of umbilical cord stem cells in treating adults in the short term.
A key opportunity in the global umbilical cord stem cells market is the increasing clinical evidence coming to the fore about umbilical cord stem cells being useful in treating more than just blood diseases. For instance, reports suggesting the ability of umbilical cord stem cells to repair cardiovascular tissues could lead to a major breakthrough in the coming years. However, these possibilities will remain limited to research facilities until scientists can find ways to reproduce the desired results in different patients.
The leading companies that have established a firm standing in the global umbilical cord stem cells market have been profiled and analyzed in the report. These companies include NeuroNova AB, Neuralstem, NeuroGeneration, ReNeuron Limited, StemCells, Asterias Biotherapeutics, STEMCELL Technologies, Thermo Fisher Scientific, Axol Bio, and Lonza.
Interested in report: Please follow the below link to meet your Requirements http://www.qyresearchreports.com/report/global-umbilical-cord-stem-cells-market-research-report-2021.htm
This report studies the global umbilical cord stem cells market in North America, Europe, Southeast Asia, China, India, and Japan. The market is studied based on the following product types: Type I, type II, and type III. The key application areas studied include: hospitals, medical care, and laboratories.
Trending Reports:
- Global Epithelial Stem Cells (ESCs) Market Report 2016
- Global Fetal Stem Cells Sales Market Report 2021
- Global Cord Blood Stem Cells Sales Market Report 2021
For Latest Market Research News Visit @ http://www.qyresearchreports.com/qyresearch-news.htm
About Us
QYResearchReports.com is the trusted source of market research reports among clients that include prestigious Chinese companies, multinational companies, SMEs, and private equity firms. Our market research reports focus on categories including but not limited to: Chemicals, Energy, Alternative and Green Energy, Machinery, Manufacturing, Glass, Pharmaceuticals and Materials READ MORE
QYResearchReports 1820 Avenue M Suite #1047 Brooklyn, NY 11230 United States Toll Free: 866-997-4948 (USA-CANADA) Tel: +1-518-621-2074 Email: [email protected] Website: http://www.qyresearchreports.com
